ICAHN ENTERPRISES L.P. Q3 FY2026 earnings call

• Strategic Acquisition: CVI announced a transformative $4.2 billion acquisition of two refineries and a marketing platform. This transaction is highly accretive, expected to increase CVR's pro forma EBITDA by over $1 billion and EPS by more than 105%.
• Liquidity Management: IEP committed to a $500 million backstop for the CVI acquisition, which will be reduced dollar-for-dollar by a concurrent CVI equity offering, meaning IEP likely won't need to fund the backstop. Senior notes maturing in May 2027 may become callable in November 2026; management expects to address these using available liquidity.
• Portfolio Performance: Sentry reported strong double-digit growth in pipeline and sales, though its stock declined ~34% in Q3. IFF authorized a $2.5 billion share repurchase program and saw a ~5% stock increase. Caesars showed continued positive performance in regional and digital businesses, with shares down ~2%.
• Operational Updates: CVR received a 100% small refiner waiver at Windywood Refinery. The East Dubuque fertilizer facility is back online, positioning the business to benefit from tight nitrogen supplies. The Transcend trial for PAH drugs is on schedule with four active sites.
• Divestitures: The sale of Pep Boys closed in Q3, generating $645 million in proceeds and a $215 million pre-tax gain. Real estate assumed certain operating leases from this sale.

The report does not provide explicit revenue contribution percentages for each segment. However, adjusted EBITDA figures are provided as follows: The Energy Segment reported an adjusted EBITDA of $404 million, a significant increase from $98 million in the prior year quarter, driven by record earnings at CVR and strong refining operations. The Investment Funds segment experienced a negative return; excluding refining hedges, the return was -5.5%, but including these hedges, the return dropped to -31.3%. The Automotive Segment recognized a pre-tax gain of $215 million from the sale of Pep Boys, with service revenues decreasing by $175 million year-over-year due to this divestiture. Real Estate’s adjusted EBITDA increased by $11 million year-over-year, largely due to income from assets transferred from the automotive segment. Food Packaging’s adjusted EBITDA rose by $2 million, driven by volume increases and improved price/product mix. Home Fashions’ adjusted EBITDA remained consistent despite soft hospitality demand. Pharma’s adjusted EBITDA decreased by $4 million due to generic competition in anti-obesity therapies and increased R&D expenses.

• CVI Transaction Outlook: Management expects the acquired assets to generate substantial cash flow over the next 12 months and beyond, citing a favorable refining environment.
• Note Management: No specific forward-looking guidance on debt repayment timing, but management indicated they expect to address senior notes maturing in May 2027 in the coming months, leveraging significant flexibility in liquidity.
• Distribution Policy: The Board declared an unchanged quarterly distribution of 50 cents per depository unit, indicating stability in shareholder returns despite market volatility.

• Market Volatility: The investment funds suffered a severe negative return of -31.3% when including refining hedges, highlighting exposure to commodity price fluctuations and hedge losses.
• Competitive Pressure: Pharma segment performance was negatively impacted by generic competition in their anti-obesity drug therapy, leading to reduced sales.
• Supply Chain Disruptions: Continued supply chain disruptions in the Strait of Hormuz have affected the Home Fashions segment.
• Regulatory/Operational Dependencies: CVR’s results were previously negatively impacted by the East Dubuque turnaround, showing sensitivity to operational downtime and regulatory waivers (e.g., small refiner status).

Q: What is the strategic rationale behind the CVI acquisition, and how does it impact IEP's liquidity?

A: Management highlighted that the $4.2 billion acquisition is highly accretive, projected to boost CVR's pro forma EBITDA by over $1 billion and EPS by more than 105%. To support this, IEP committed to a $500 million backstop, but this commitment will be fully offset by a concurrent CVI equity offering, preserving IEP's liquidity. The transaction adds strong cash-generating assets at an attractive valuation of less than 3.5 times 2026 EBITDA.

Q: How did the refining hedges affect the investment funds' performance, and what is the current exposure?

A: The CFO explained that while the funds had a modest -5.5% return excluding refining hedges, the inclusion of these hedges resulted in a steep -31.3% decline for the quarter. Despite this loss, the funds shifted significantly toward long positions; net short exposure dropped from 30% to 7%, while net long exposure (excluding hedges) rose from 23% to 57%, indicating a strategic pivot to capitalize on the favorable refining environment.

Q: What are the key drivers behind the changes in the Pharma and Home Fashions segments?

A: Pharma’s adjusted EBITDA fell by $4 million primarily due to generic competition eroding sales in their anti-obesity drug line and higher R&D costs for pivotal trials. Conversely, Home Fashions maintained consistent EBITDA despite headwinds. Management noted that while hospitality demand softened and Strait of Hormuz disruptions persisted, the business managed to hold steady, though no major upside was reported compared to other segments.